5 Mar, 2018

Spago Nanomedical to be granted US patent for Tumorad®

Spago Nanomedical have received a Notice of Allowance indicating that the United States Patent and Trademark Office (USPTO) intend to grant the company´s patent application comprising product protection for Tumorad® in the USA.

The patent (Nanostructures and applications thereof, 15/129,229) means that Spago Nanomedical gains product protection for Tumorad® in the USA, one of the strategically most important markets for radionuclide therapies. It includes the company´s unique nanoparticles and will secure market exclusivity in the USA until at least 2035.

”Strong patents are key components for future outlicensing. The current patent will provide excellent product protection for Tumorad® in the single most important market for cancer therapies”, says Mats Hansen, CEO of Spago Nanomedical.

The application for product protection is submitted in all substantial markets and further approvals in e.g. EU and Japan are pending.

Tumorad® is currently in lead optimization phase and activities for fine tuning the material with regards to circulation time in vivo are ongoing. The aim is to enter preclinical proof of concept studies as soon as possible.

For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, mats.hansen@spagonanomedical.se.

Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.

Tumorad® is a new type of radionuclide therapy based on Spago Nanomedical´s proprietary nanoparticles and a therapeutically relevant radioisotope for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer.

The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on 5 March, 2018.

For further information, see www.spagonanomedical.se.

Spago Nanomedical to be granted US patent for Tumorad®